Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ESTA
SellHot AirEstablishment Labs Holdings Inc. · Healthcare · United States · $2.1B · Avg Vol: $35M/d
COMPANY DESCRIPTION
Establishment Labs Holdings Inc. is a global medical technology company focused on women's health, specializing in the design, development, and commercialization of advanced silicone gel breast implants under its Motiva brand. The company differentiates itself through product innovation, safety features, and a premium market position, aiming to disrupt the established aesthetic breast implant market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 161.7M | 165.2M | 166.0M | 211.1M | 9.3% | 245.8M | 270.2M | 339.2M | 26.8% |
| EPS | -3.08 | -3.07 | -3.00 | -1.72 | — | -1.27 | -1.10 | 0.06 | — |
| Shares | 24.4M | 26.1M | 28.8M | 29.3M | +20.1% | 29.8M | — | — | — |
| Debt | 179.3M | 192.2M | 225.3M | 264.5M | 13.8% | 263.7M | — | — | — |
| Equity | -8.2M | 18.4M | 53.1M | 23.5M | 13.1% | — | — | — | — |
| Op CF | -52.2M | -88.5M | -58.5M | -50.9M | — | -32.3M | — | — | — |
| Inv CF | -34.8M | -24.5M | -15.6M | -7.0M | — | — | — | — | — |
| Fin CF | 100.3M | 86.2M | 125.9M | 40.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ESTA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ESTA | Establishment Labs Holdings Inc.(you) | $2.1B | 23 | Sell |
| ALMR | Alamar Biosciences, Inc. | $2.1B | 20 | Sell |
| ATEC | Alphatec Holdings, Inc. | $1.5B | 27 | Sell |
| TMDX | TransMedics Group, Inc. | $3.1B | 28 | Sell |
| TNDM | Tandem Diabetes Care, Inc. | $1.5B | 31 | Sell |
| LMRI | Lumexa Imaging Holdings, Inc. | $1.1B | 28 | Sell |
| BFLY | Butterfly Network, Inc. | $2.2B | 41 | Hold |
| PRCT | PROCEPT BioRobotics Corporation | $1.2B | 15 | Strong Sell |
| CBLL | CeriBell, Inc. | $911M | 27 | Sell |
| QDEL | QuidelOrtho Corporation | $1.0B | 29 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%